Skip to main navigation
ARS Pharma
- ARS Pharma - Investor Relations
  • About Us
    • Meet Our Team
    • Careers
    • Job Openings
  • Product
    • neffy
      • neffy 2mg
      • neffyConnect
      • Prescribing information
    • Pipeline
  • Investors & Media
    • Events & Presentations
    • Press Releases
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
      • Compliance Program
    • IR Resources
      • Email Alerts
      • Stay Connected
    • Scientific Presentations
  • Stay Connected
  • Community Program
    • neffyinSchools
  • Contact Us

Press Releases

Jan 21, 2025
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
Jan 13, 2025
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
Jan 06, 2025
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

©2024 ARS Pharmaceuticals Operations, Inc.  All rights reserved.  “ARS Pharma,” the ARS Pharma logo design, “neffy,” the neffy logo, and the neffyconnect logo are trademarks or registered trademarks of ARS Pharmaceuticals Operations, Inc. Generic references to ARS Pharma refer to ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) and/or its wholly-owned operations subsidiary,

Privacy Policy  |  Terms of Use

This site is intended for U.S. visitors only.